Interpreting Hematology Scatter-Plots; One Cancer Center s Keys to Seeing the BIG Picture

Similar documents
10/30/2015. XN Case Studies: Every Picture Tells a Story

LEANING Away Waste and Improving Patient Care with Advances in Hematology

Sysmex Journal International Vol.9 No.2 (1999)

Full Blood Count analysis Is a 3 part-diff good enough? Dr Marion Münster, Sysmex South Africa

XN-SERIES. XN Technology and Case Studies

3. Blood Cell Histograms:

XN-SERIES. Hematology Case Studies: Every Picture Tells a Story

Evaluation of the Diagnostic Performance of the Sysmex XT-2000i Automated Hematology Analyzer in the Detection of Immature Granulocytes

Combining. and New Diagnostic. to Help Clinicians Achieve. Patient Outcomes at. per Healthcare Encounter

Hematology 101. Cindy Rogers, MT(ASCP) Diagnostics System Specialist

Lavender Top Management SUCCESS BEYOND FINANCES. Mission/ Vision

HumaCount 5D. Outperforming 5-part Hematology System. CoreLab DX. Hematology

Lavender Top Management SUCCESS BEYOND FINANCES

Guide to the 1-3 Minute Blood Film Microscopic Review: Why and How?

5/1/2017 DISCUSSION POINTS. Clinical Utility of Immature Cell Indices Beyond the Routine CBC John E. Donnelly BSN, RN

of s and s Disclosure

Differential Blood Smear H3

It s Easier Than you Think How to Implement the Advanced Clinical Parameters

Proper Slide Preparation

Standard Operating Procedure

CELL-DYN Strength in Technology, Proven Reliability. Optical WBC Technology. Patented M.A.P.S.S. Differential. Multiple Technologies

INFECTION/ INFLAMMATION

A Look Into the Determination of Cell Morphology in Hematology in the 21 st Century. Ramon Simon-Lopez, MD Global Scientific Director Beckman Coulter

CASE STUDIES PERIPHERAL BLOOD AND BODY FLUIDS

DR SUDHIR MEHTA MD,MNAMS,FICP. Senior Professor & Head Medical Unit SMS Medical College & Hospital Jaipur

3/31/2017 OBJECTIVES CASE STUDY #1 MANUAL REVIEW. Hematology Case Studies: Every Picture Tells a Story

Precision and Accuracy of the Leukocyte Differential on the Sysmex XE-2100

Hematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

9/23/2018. Hematology Case Studies Jason Anderson, MPH, MT(ASCP) Field Product Specialist OBJECTIVES FLUORESCENT FLOW CYTOMETRY

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Disclosures/COI. Cases in Hematopathology. Outline. Heme Path Findings Not to Miss. Normal Peripheral Smear 6/30/2016

NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TEST PROGRAM Glass Slide - November 2016

Kathleen Finnegan MS MT(ASCP)SHCM

Complete Blood Count (CBC) Assist.Prof. Filiz BAKAR ATEŞ

Differential Blood Smear H3

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

Hematology & Coagulation Practicum Objectives CLS - 647

CELL-DYN 3700 Strength in Technology, Proven Reliability

Interpreting the CBC. Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired

Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and

Use of the XE-2100 in a Patient with Cold Auto-immune Hemolytic Anemia

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?

Patterns of Lymphoid Neoplasia in Peripheral Blood. Leon F. Baltrucki, M.D. Leon F. Baltrucki, M.D. Disclosure

Auto Validation and Management Reports Using Sysmex WAM. Alfonso Ziccardi Laboratory Operation Manager for AP/CP/Safety Officer

Hematopathology Case Study

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Clinical use of flow cytometry

Does Morphology Matter in 2017

Evaluation of Coulter S-Plus Three-part Differential in Population with a High Prevalence of Abnormalities

XN series. Case interpretation. Gebruikersdag Vlaanderen- 6 oktober 2016

Differential Blood Smear H3

Peripheral Blood Smear: Diagnostic Clues and Algorithms

Sue Jung Kim, MD, MS; Yoonjung Kim, MD; Saeam Shin, MD; Jaewoo Song, MD, MS; Jong Rak Choi, MD, PhD

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Blood Cell Identification Graded

Automated Hematology Analyzer. Differentiate with the XT-4000i

A Practical Approach to Leukopenia/Neutropenia in Children. Vandy Black, M.D., M.Sc., FAAP OLOL Children s Hospital August 24, 2014

The Evolving Role of Reticulated Platelets

Customer Information Literature List White Blood Cells

Optimization of Criteria for Verification of Automated Platelet Counts Generated by the Sysmex XE-2100 Hematology Analyzer

2013 AAIM Pathology Workshop

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls

Myelodysplastic Syndrome: Let s build a definition

First comparative evaluation of leucocyte differential and reticulocyte count between Abbott Cell -DYN 3700 and Beckman-Coulter Gen S

Getting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation.

Advanced parameters offer faster, surer guidance to cancer care

Myelodysplastic Syndrome Case 158

Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss

Complete Blood Count PSI AP Biology

Hematology Essentials: A Foundation for Accurate Smear Reviews. Christine Hinz, MS, MLS(ASCP) CM

Ordering Physician CLIENT,CLIENT. Collected REVISED REPORT

Hematology Case Conference 8/5/03

HEMATOLOGIC MORPHOLOGY- AECOM HEMATOLOGY COURSE

EDUCATIONAL COMMENTARY DISTINGUISHING MORPHOLOGIC LOOK-ALIKES

BACKGROUND. Absolute neutrophil counts (ANCs) and absolute phagocyte counts

MDS: Who gets it and how is it diagnosed?

Case Presentation. Attilio Orazi, MD

Matthew Ulrickson, MD Banner MD Anderson Cancer Center September 12, 2017

Evidence-Based Hematological Solutions

Extramedullary precursor T-lymphoblastic transformation of CML at presentation

+ Bloodsmear exam 1/12/2014. Goals. Instrument Technologies

GOOD MORNING! Thursday, July Heidi Murphy, MD Leslie Carter-King, MD

Brief Communication Diagnostic Hematology

CLINICAL STUDY REPORT SYNOPSIS

Scoring System for Detecting Spurious Hemolysis in Anticoagulated Blood Specimens

Tim R. Randolph. PhD, MT(ASCP) Chair and Associate Professor Department of Biomedical Laboratory Science Saint Louis University

HAEMATOLOGICAL EVALUATION OF ANEMIA. Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore

Haematologist-reviewed peripheral blood smear in paediatric practice

Nationwide Children s Hospital

Laboratory Testing for the Primary Care Optometrist

Clinical implications for decreased lymphocytes (lymphopenia) o Corticosteroid therapy, adrenocortical hyperfunction, stress, shock

EDUCATIONAL COMMENTARY BLOOD CELL IDENTIFICATION

The importance of thrombocytopenia and its causes

EDUCATIONAL COMMENTARY MORPHOLOGIC CHANGES IN PERIPHERAL BLOOD CELLS

CHALLENGING CASES PRESENTATION

بسم هللا الرحمن الرحيم

Case Presentation No. 075

Clinical Utility. Clinical Utility of the Automated IG-Count Xavier Troussard

Transcription:

Interpreting Hematology Scatter-Plots; One Cancer Center s Keys to Seeing the BIG Picture Barbara L. Burch, MHA MT (ASCP) Laboratory Manager New York University Clinical Cancer Center Disclosure Ms Burch is receiving an honorarium for Ms Burch is receiving an honorarium for her participation in this educational event 1

Learning Objectives Give 3 examples of how Complete Blood Count results are used in the care of oncology patients. Give 2 examples of how practiced Scatter- Plot interpretation improves oncology patient care while providing timely and reliable results to the clinician. Identify 2 keys to begin more advanced hematology Scatter-Plot interpretation. Current laboratory staffing trends: 1. Decrease in number of accredited schools 2. Decrease in number of students entering field 3. Bye Bye Baby Boomers 4. Under-recognition of Laboratory Medicine field inside and outside of Healthcare 5. Decrease in reimbursement for services 6. Laboratory testing volume is on the rise 2

Doing more with less Lab Automation LIS Auto-Verification POCT Cross-Training Thorough information interpretation? Playing it safe! Hold the results wait for slide confirmation Catch the false negatives Manufacturer says to % or absolute cut off = manual diff Blasts counted as Monos Manual WBC s and PLT s 3

Routine CBC s Infections viral or bacterial Anemia inherited or acquired (acute or chronic) Thrombocytopenia Leukemias CBC s in Oncology Chemotherapy and Radiation Treatments act by interfering i with cell division: i i Neutropenia Thrombocytopenia Anemia Treatments to counteract above side effects: Neupogen/Neulasta Plt Transfusion Pro-Crit/Aranesp, RBC Transfusion 4

Oncology cont d Recurrence of leukemia NRBC s Response to growth factor or tumor invasion of bone marrow? Accurate WBC, ANC, Hgb and PLT results needed d QUICKLY for treatment decisions!! Fluorescent NRBC 5

Removal NRBC influence from WBC and DIFF count Total WBC Count WBC - Minus NRBC Correct WBC# DIFF - Minus NRBC Correct Differentials + + 6

Platelet Clumps Plt Clumps Ghost HPC IMI Channel RF RF IMI Scattergram PLT CLUMPS Ghost Ghost Immature Gran Blasts HPC DC 7

Fluorescent Optical Plt RBC Frags Lg Plts 8

Extended Diff IG Example Extended Diff IG Example Cont. Follow up: Adiff reported as is and smear review was done to evaluate Blast flag there were none. 9

Using the IMI Channel Example Using the IMI Channel Monos???? 10

Using the IMI Channel Patient s Manual Diff Neu % = 16 Lymph h% = 39 Atyp Lym% = 10 Mono % = 0 Myelo % = 1 Promeylo % = 1 Blasts % = 33 NRBC s = 5/100 WBC s Auer Rods Seen Pt has untreated AML Using the IMI Channel - 2 11

Using the IMI Channel - 2 Using the IMI Channel - 2 MANUAL DIFFERENTIAL Segs = 96% Lymphs = 3% Monos = 0% Eos = 1% Hyper-segmentation of Neutrophils (No plt clumps) 12

Using the IMI Channel - 2 Hypersegmented Neutrophils = more nucleic acid = more fluorescence. Platelet Clumps - Example 13

Plt Clumps Example continued Typical IMI plt clump tail Plt Clumps Example continued Smear: 14

NRBC s Example 1 NRBC s Example 1 continued Uncorrected WBC = 2.0 Treatment decision cutoff = WBC must be > 2.0 Corrected WBC = 1.9 below treatment requirements Next step look at ANC 15

NRBC s Example 2 NRBC s - Example 2 continued Instrument gives no reliable differential information other than the NRBC s. WBC corrected for 30% NRBC s. However 16

NRBC s Example 2 continued Patient s Manual Diff Neu % = 15 Bands % = 1 Lymph % = 40 Mono % = 1 Atyp Lym% = 43 NRBC s = 72/100 WBC s Micromegakaryocytes = 19/100 WBC s Micromegakaryocyte nuclear fragments 15/100 WBC s NRBC count higher on manual Further WBC correction needed, diff because the instrument is however initial correction is done counting the MMKC s as by the analyzer so the final WBC s. correction is not as drastic. Blast Micro-Megakaryocyte Micro-Megakaryocyte y Abnormal Platelets 17

Plts and RBC Frags Example Plts and RBC Frags Example MOAN AND GROAN What we were taught to do Rerun and pray for a fitted curve Check MCV; is it low? Check MPV; is it high? Hurry up and stain the smear and check under the scope If RBC fragments/microcytes or Lg Plts present; Do manual smear estimate OR Do hemacytometer count What the cancer center does Rerun an optical plt count 18

Plts and RBC Frags Example cont. Plts and RBC Frags Example cont. Normal Optical Plt Scattergram Patient Optical Plt Scattergram RBC Fragments RBC Fragments 19

Plts and RBC Frags Example cont. Smear: Outcome: Optical plt count verified and released. No smear review done. Optical Platelet Example 20

Optical Platelet Example cont. Outcome: Optical count reported without smear follow up, patient treated. Clean Separation Just Plain Interesting 66 yr old female ovarian cancer remission Presented with: Fevers/chills Steadily decreasing Plt count and H&H Steadily increasing LDH Hematology consult resulted in workup for: DIC Auto-AbAb Lyme disease, etc. Septicemia Babesia/Malarial Infection 21

Just Plain Interesting Still Just Plain Interesting 22

Just Plain Interesting Where are they??? 23

Compare Babesia Patient Time of Dx Optical Count 86 Optical Count 64 3 Weeks post treatment. PLT-I = 357 PLT-O =351 Total WBC Case 24

Total WBC Case Total WBC Case 25

Total WBC Case Total WBC Case Diff Channel Count WBC/BASO Count Patient has Multiple Myeloma significant rouleaux seen on slide. WBC smear estimate matched Diff Channel Count. 26

Let s put it all together Let s put it all together cont. IG counted in Diff Channel AND there is activity in the IMI Re-Ran Optical Plt Count: 27

Let s put it all together cont. Outcome: All results released and Optical plt count without smear verification. Smear review done and showed left shift Myelocytes, 1+ Toxic Gran and Dohle Bodies. Keys to Scatter-Plot Interpretation UNDERSTAND the technology! Know where all the information is Know where the flags are generated from Look for correlating information in more than one scatter-plot/histogram Develop decision trees Look for patterns in scatter-plots and what is seen on the slide What is REALLY important to your clinicians? 28

QUESTIONS??? Barbara Burch email Barbara.burch@nyumc.org 29